ArticleRadiation oncology (London, England)2019
Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma.
Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.BMC cancer · 2024Trial
- Multimodal PET-MR segmentation for glioblastoma: complementarity for treatment planning and recurrence definition.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Young adults with primary brain tumors: predictors of referral to a fertility specialist for fertility preservation counseling and the impact on tumor treatment.Journal of neuro-oncology · 2026Article
- EGFR Amplification in Diffuse Glioma and Its Correlation to Language Tract Integrity.Diagnostics (Basel, Switzerland) · 2025Article
- Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.BMC medicine · 2024Review
- Optimal timing of chemoradiation after resection or biopsy of glioblastomas: a nationwide population-based study.BMC cancer · 2024Article
- Choreographed expansion of services results in decreased patient burden without compromise of outcomes: An assessment of the Ontario experience.Neuro-oncology practice · 2024Article
- The role of GammaTile in the treatment of brain tumors: a technical and clinical overview.Journal of neuro-oncology · 2024Review
- Evaluation of Inequities in Cancer Treatment Delay or Discontinuation Following SARS-CoV-2 Infection.JAMA network open · 2023Article
- Unplanned intensive care unit readmission after surgical treatment in patients with newly diagnosed glioblastoma - forfeiture of surgically achieved advantages?Neurosurgical review · 2023Article
- Impact of Rural vs. Urban Residence on Survival Rates of Patients with Glioblastoma: A Tertiary Care Center Experience.Brain sciences · 2022Article
- FACTORS AFFECTING OUTCOME IN THE TREATMENT OF GLIOBLASTOMA.Acta clinica Croatica · 2022Article
- Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.Frontiers in oncology · 2022Article
- Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy.International journal of radiation oncology, biology, physics · 2021Article
- Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US.Journal of neuro-oncology · 2021Article
- The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence.International journal of molecular sciences · 2021Review
- Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents.Future medicinal chemistry · 2021Review
- Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in glioblastoma surgery.PloS one · 2021Article
- Sonodynamic therapy in combination with photodynamic therapy shows enhanced long-term cure of brain tumor.Scientific reports · 2020Article
- Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeTo evaluate the effect of timing of radiotherapy (RT) on survival in patients with newly diagnosed primary glioblastoma (GBM) treated with the same therapeutical protocol. MATERIALS AND
methodsPatients with newly diagnosed primary GBM treated with the same therapeutical scheme between 2010 and 2015 in our institution were retrospectively reviewed. The population was trichotomized based on the time interval from surgery till initiation of RT (< 28 days, 28-33 days, > 33 days). Kaplan-Meier and Cox regression analyses were used to compare progression free survival (PFS) and overall survival (OS) between the groups. The influence of various extensively studied prognostic factors on survival was assessed by multivariate analysis.
resultsOne-hundred-fifty-one patients met the inclusion criteria. Between the three groups no significant difference in PFS (p = 0.516) or OS (p = 0.902) could be demonstrated. Residual tumor volume (RTV) and midline structures involvement were identified as independent prognostic factors of PFS while age, O-6-Methylguanine Methyltransferase (MGMT) status, Ki67 index, RTV and midline structures involvement represented independent predictors of OS. Patients starting RT after a prolonged delay (> 48 days) exhibited a significantly shorter OS (p = 0.034).
conclusionInitiation of RT within a timeframe of 48 days is not associated with worsened survival. A prolonged delay (> 48 days) may be associated with worse OS. RT should neither be delayed, nor forced, but should rather start timely, as soon as the patient has recovered from surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.